Sotorasib - Isotope Labelled Standards
References
FAQ's
References
- Lanman, Brian Alan; Chen, Jian; Reed, Anthony B.; Cee, Victor J.; Liu, Longbin; Kopecky, David John; Lopez, Patricia; Wurz, Ryan Paul; Nguyen, Thomas T.; Booker, Shon; et al, KRAS G12C inhibitors and methods of using the same, Amgen Inc., United States, US10519146B2, December 31, 2019
- Wong, Philip; Akrami, Anna; Houk, Brett; Vuu, Irene; James, Christopher A., Validation of an LC-MS/MS method for the determination of sotorasib, a KRASG12C inhibitor, in human plasma, Bioanalysis, Volume: 14, Issue: 19, Pages: 1281-1292, 2022
Frequently Asked Questions
How are Sotorasib impurities formed?
Impurities form during the synthesis of Sotorasib or storage. They can also occur due to chemical reactions with other substances.
What are the most common Sotorasib impurities?
The most common impurities found in Sotorasib are related compounds, degradation products, and residual solvents.
Which solvent helps in the analysis of Sotorasib impurities?
DMSO is the solvent used in analyzing many impurities in Sotorasib.
What are the temperature conditions required to store Sotorasib impurities?
Sotorasib impurities are stored at a controlled room temperature between 2-8 ⁰C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.